Hopital de la Timone

Running trials

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Source

• Not yet recruiting

  An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM

  NCT07867886· Source

• Recruiting

  Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease

  2024-518437-28-00· Phase 3· Source

• Recruiting

  BIO|STREAM.CSP Study

  NCT07393009· Source

• Recruiting

  Assessment of the Clinical and Economic Impact of Sim&Size, a Simulation Software for Implantable Devices Used in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study.

  NCT07433075· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Source

• Recruiting

  Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

  NCT03593317· Phase 2· Source

• Active, not recruiting

  Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

  NCT06333951· Phase 1· Source

• Recruiting

  French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

  NCT06147843· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

  NCT06402838· Phase 2· Source

• Recruiting

  A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

  NCT05639413· Source

• Active, not recruiting

  ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

  NCT05928416· Source

• Recruiting

  PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

  NCT05387954· Phase 3· Source

• Recruiting

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Phase 3· Source

• Active, not recruiting

  An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

  NCT05876754· Phase 3· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Source

• Recruiting

  First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

  NCT05601726· Phase 1/2· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Source

• Recruiting

  Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years

  NCT05373940· Source

• Recruiting

  Hizentra® in Inflammatory Neuropathies - pHeNIx Study

  NCT04672733· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  NCT05071300· Phase 3· Source

• Active, not recruiting

  French eCLIPs™ Efficacy and Safety Investigation

  NCT05330897· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Source

• Recruiting

  Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

  NCT04747054· Phase 3· Source

• Active, not recruiting

  Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

  NCT04919811· Phase 2· Source

• Active, not recruiting

  Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

  NCT04960709· Phase 3· Source

• Recruiting

  Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

  NCT04698785· Phase 2· Source

• Active, not recruiting

  Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

  NCT04704934· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT04663347· Phase 1/2· Source

• Recruiting

  Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

  NCT04477681· Source

• Active, not recruiting

  A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

  NCT04183166· Phase 1/2· Source

• Active, not recruiting

  Inspiris Resilia Durability Registry

  NCT03666741· Source

• Active, not recruiting

  Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study

  NCT03183895· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Source

• Recruiting

  FARD (RaDiCo Cohort) (RaDiCo-FARD)

  NCT05954416· Source

• Recruiting

  IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

  NCT05945576· Source

• Active, not recruiting

  Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

  NCT03022188· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Source

• Active, not recruiting

  Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

  NCT02243605· Phase 2· Source

• Active, not recruiting

  Vismodegib in Treating Patients With Advanced Chondrosarcomas

  NCT01267955· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Heart failure3 recruiting
• Colorectal cancer2 recruiting
• Head and neck cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Amyloidosis1 recruiting
• Brain aneurysm1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Source

• Completed

  Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia

  NCT05053932· Source

• Completed

  A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

  NCT05258071· Phase 2· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

  NCT05423522· Phase 2· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

  NCT05116202· Phase 1/2· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Source

• Completed

  Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

  NCT04732494· Phase 2· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

  NCT04216953· Phase 1/2· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Completed

  SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

  NCT03806452· Phase 2· Source

• Completed

  FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

  NCT03723967· Phase 2· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· Source

• Completed

  A Study of BAX 888 in Male Adults With Severe Hemophilia A

  NCT03370172· Phase 1/2· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· Source

• Completed

  Predictive Factors and Subthalamic Stimulation in Parkinson's Disease

  NCT02360683· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

  NCT01467427· Phase 3· Source